IMR Press / CEOG / Volume 46 / Issue 6 / DOI: 10.12891/ceog4977.2019

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Lymphocyte-monocyte ratio predicts uterine sarcoma aggressiveness
Show Less
1 Department of Obstetrics and Gynecology, The Catholic University of Korea, Seoul, Korea
2 Department of Pathology, The Catholic University of Korea, Seoul, Korea
3 Department of Obstetrics and Gynecology, Hallym University College of Medicine, Seoul, Korea
4 Department of Obstetrics and Gynecology, Busan, Korea
5 Department of Obstetrics and Gynecology, Eulji University. Seoul, Korea
6 Kosin University Graduate School, Busan, Korea
*Correspondence: (EUN JOO PARK)
Clin. Exp. Obstet. Gynecol. 2019, 46(6), 953–957;
Published: 10 December 2019

Purpose of Investigation: The aim of the current study is to assess the prognostic value of the lymphocyte-monocyte ratio (LMR) in patients with uterine sarcoma. Materials and Methods: The authors examined the LMR as a prognostic variable in a cohort of 66 patients with uterine sarcoma who underwent surgical resection. Patients were categorized into two groups based on the LMR using cut-off values determined by receiver operating characteristic curve (ROC) analysis. They assessed the effect of the LMR on progression-free survival (PFS) and validated the LMR as independent predictor of survival. Results: Using data from the whole cohort, the optimized LMR cut-off value selected using the ROC curve was 5.86 for PFS. The LMR-low and LMR-high groups included 45 (68.2%) and 21 (31.8%) patients, respectively. The five-year PFS rates in the LMR-low and LMR-high groups were 69.0% and 94.4%, respectively (p= 0.024). Via multivariate analysis, the authors identified FIGO stage, residual tumor after surgery, and LMR as the most valuable prognostic factors affecting PFS (p = 0.039, p = 0.018, and p = 0.043, respectively). Conclusion: The LMR is an independent prognostic factor affecting the PFS of patients with uterine sarcoma.

Uterine neoplasms
Uterine sarcoma
Back to top